SCHAUMBURG, Ill. & BAD HOMBURG V.D.H., Germany--(BUSINESS WIRE)--APP Pharmaceuticals, Inc. (Nasdaq:APPX) and Fresenius SE (XETRA:FRE) have received confirmation that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of APP Pharmaceuticals by Fresenius Kabi, a business segment of Fresenius SE. The FTC granted early termination of the waiting period under the Hart-Scott-Rodino Act without conditions. The German antitrust authorities had already approved the acquisition.
